Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors

In the latest close session, Astrazeneca (AZN) was down 1.72% at $82.61. This change lagged the S&P 500's daily gain of 0.23%. Elsewhere, the Dow saw an upswing of 0.34%, while the tech-heavy Nasdaq appreciated by 0.8%. The stock of pharmaceutical has risen by 13.4% in the past month, leading the Medical sector's gain of 5.57% and the S&P 500's gain of 3.57%.Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on November 6, 2025. The company's earnings per share (EPS) are projected to be $1.14, reflecting a 9.62% increase from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $14.86 billion, indicating a 9.57% increase compared to the same quarter of the previous year. For the full year, the Zacks Consensus Estimates project earnings of $4.56 per share and a revenue of $58.24 billion, demonstrating changes of +10.95% and +7.71%, respectively, from the preceding year. Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Right now, Astrazeneca possesses a Zacks Rank of #3 (Hold). Looking at its valuation, Astrazeneca is holding a Forward P/E ratio of 18.43. This signifies a discount in comparison to the average Forward P/E of 19.33 for its industry. Investors should also note that AZN has a PEG ratio of 1.55 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. AZN's industry had an average PEG ratio of 1.62 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 89, putting it in the top 37% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow AZN in the coming trading sessions, be sure to utilize Zacks.com. Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks